Issue 7 - Feb 14, 2020
Issue 6 - Feb 7, 2020
Issue 5 - Jan 31, 2020
  • Conversation with The Cancer Letter

    Thomas Lynch lists his areas of emphasis at the Hutch:

    Solid tumors, immuno-oncology, Big Data, microbial involvement

     On Feb. 1, Thomas J. Lynch will report to work as president and director of Fred Hutchinson Cancer Research Center.

  • SU2C initiatives aim to boost diversity in cancer trials

    Stand Up To Cancer has launched two initiatives to increase minority representation in cancer clinical trials by amending its grant application requirements and funding a new research team focused on diversity and inclusion.

  • Surgeon General’s report notes lack of evidence on e-cigarettes in smoking cessation

    A report by the Office of the Surgeon General finds that more than two-thirds of United States adult cigarette smokers report interest in quitting cigarette smoking; and the majority of adult cigarette smokers in the U.S. have tried to quit during the past year.

  • In Brief

    • New cancer center established at Hopkins
    • Eileen Smith appointed chair of Hematology & Hematopoietic Cell Transplantation at City of Hope
    • UCLA receives $18M to expand whole-person care for cancer patients and families
    • Atefeh Riazi named chief information officer at MSK
    • Usama Gergis named head of BMT and cell-based therapy program at Thomas Jefferson
    • Ragini Kudchadkar named chair of Clinical and Translational Review Committee at Emory
    • Theresa Guise becomes CPRIT Scholar Number 200
    • Medicaid block grants threaten beneficiary access to cancer care, ASCO says
    • National Brain Tumor Society funds  ONC201 trial in EGFR-independent high-grade gliomas
    • FNIH accepting nominations for Trailblazer prize
  • TCCL Logo

  • Clinical Roundup

    • Stem cells, CRISPR and gene sequencing technology are basis of brain cancer model
    • HIV outcomes improved by state-purchased insurance plans
  • Drugs & Targets

    • Predictive Technology Group and Atrin Pharmaceuticals collaborate on molecular diagnostic oncology development